Autolus Therapeutics (AUTL) director gains new option and RSU awards

Rhea-AI Filing Summary

Autolus Therapeutics plc director Michael W. Bonney received new equity-based compensation. He was granted options to buy 47,500 American Depositary Shares at an exercise price of $1.61 per share, vesting in twelve equal monthly installments starting on July 29, 2026.

He also received 31,667 restricted share units, each representing one American Depositary Share, which vest in a single installment on June 29, 2027. These awards increase his potential future ownership but are subject to time-based vesting.

Insights

Equity compensation and governance analyst

Director receives routine option and RSU grants with future vesting.

Director Michael W. Bonney was granted 47,500 share options with a $1.61 exercise price and 31,667 RSUs, all tied to Autolus Therapeutics plc American Depositary Shares. Both awards are classified as grant or award acquisitions, not market purchases.

The RSUs vest on June 29, 2027, while the options vest monthly over twelve installments starting July 29, 2026 and expire on June 29, 2036. These time-based schedules align the director’s potential equity value with longer-term service.

Since there are no open-market buys or sells and no remaining derivative positions listed, this filing reflects a standard equity compensation event rather than a signaling trade. Future company filings may show when these awards vest or are exercised.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider BONNEY MICHAEL W

Role null

Type	Security	Shares	Price	Value
Grant/Award	Restricted Share Units	31,667	$0.00	--
Grant/Award	Share Option (Right to Buy)	47,500	$0.00	--

Holdings After Transaction: Restricted Share Units — 31,667 shares (Direct, null); Share Option (Right to Buy) — 47,500 shares (Direct, null)

Footnotes (1)

1. Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's American Depositary Shares. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share. The RSUs vest in one installment on June 29, 2027. Share options vest in twelve equal monthly installments commencing on July 29, 2026.

Key Figures

Option grant size: 47,500 options Option exercise price: $1.61 per share Option expiration: June 29, 2036 +3 more

6 metrics

Option grant size 47,500 options Share Option (Right to Buy) on American Depositary Shares

Option exercise price $1.61 per share Conversion or exercise price for share options

Option expiration June 29, 2036 Expiration date of granted share options

RSU grant size 31,667 RSUs Restricted Share Units representing ADSs

RSU vesting date June 29, 2027 Single installment vesting date for RSUs

Option vesting start July 29, 2026 First monthly vesting date for options

Key Terms

Restricted Share Units, American Depositary Shares, Share Option (Right to Buy), transaction code A

4 terms

Restricted Share Units financial

"security_title: "Restricted Share Units" with 31,667.0000 underlying ADSs"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

American Depositary Shares financial

"underlying_security_title: "American Depositary Shares" for both awards"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

Share Option (Right to Buy) financial

"security_title: "Share Option (Right to Buy)" granted for 47,500 shares"

transaction code A financial

"transaction_code: "A" described as Grant, award, or other acquisition"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 04:05 PM Accepted by SEC EDGAR 07/01/2026 - 04:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BONNEY MICHAEL W

(Last) (First) (Middle)

THE MEDIAWORKS, WHITE CITY

C/O AUTOLUS THERAPEUTICS PLC

(Street)

LONDON W12 7FP

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Autolus Therapeutics plc [ AUTL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(1)	06/29/2026		A		31,667		(2)	(2)	American Depositary Shares	31,667	$0	31,667	D
Share Option (Right to Buy)	$1.61	06/29/2026		A		47,500		(3)	06/29/2036	American Depositary Shares	47,500	$0	47,500	D

Explanation of Responses:

1. Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's American Depositary Shares. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share.

2. The RSUs vest in one installment on June 29, 2027.

3. Share options vest in twelve equal monthly installments commencing on July 29, 2026.

	/s/ Michael Bonney	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Autolus Therapeutics (AUTL) director Michael Bonney receive in this Form 4?

Michael W. Bonney received equity awards, not open-market trades. He was granted 47,500 stock options at a $1.61 exercise price and 31,667 restricted share units, all tied to Autolus Therapeutics American Depositary Shares as part of his director compensation.

Are the Autolus Therapeutics (AUTL) transactions in this Form 4 insider buys or sells?

The filing reports grant or award acquisitions, not open-market buys or sells. Both entries use transaction code A, indicating compensation-related awards. The transaction summary shows two acquisitions and zero buys or sells, suggesting routine equity compensation rather than trading activity.

What are the details of Michael Bonney’s stock option grant at Autolus Therapeutics (AUTL)?

Bonney received options on 47,500 American Depositary Shares with a conversion or exercise price of $1.61 per share. These options vest in twelve equal monthly installments beginning July 29, 2026 and expire on June 29, 2036, reflecting a long-dated, time-based incentive structure.

How do the Autolus Therapeutics (AUTL) RSUs granted to Michael Bonney vest?

He was granted 31,667 restricted share units, each representing one American Depositary Share. According to the footnotes, these RSUs vest in a single installment on June 29, 2027, meaning he must remain eligible through that date to receive the underlying shares.

Do the RSUs and options in this Autolus Therapeutics (AUTL) Form 4 convert into ordinary shares?

Each RSU represents a contingent right to receive one American Depositary Share. Each American Depositary Share is convertible at any time at the reporting person’s option into one ordinary share, so these awards can ultimately translate into ordinary share ownership if vested and, for options, exercised.

Does this Autolus Therapeutics (AUTL) Form 4 indicate remaining derivative positions after the grants?

The derivative transaction entries show 47,500 options and 31,667 RSUs with totals following the transactions matching the grant sizes. The derivative position summary is empty, which in this context indicates the filing does not list additional separate derivative holdings beyond these newly granted awards.